Cargando…
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked condition caused by a deficiency of functional dystrophin protein. Patients experience progressive muscle weakness, cardiomyopathy and have a decreased life expectancy. Standards of care, including treatment with steroids, and multidisciplinary approa...
Autores principales: | Markati, Theodora, De Waele, Liesbeth, Schara-Schmidt, Urlike, Servais, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591262/ https://www.ncbi.nlm.nih.gov/pubmed/34790118 http://dx.doi.org/10.3389/fphar.2021.735912 |
Ejemplares similares
-
Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021) -
Drug development progress in duchenne muscular dystrophy
por: Deng, Jiexin, et al.
Publicado: (2022) -
Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients
por: Kameyama, Tsubasa, et al.
Publicado: (2018) -
Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study
por: Raccah, Bruria Hirsh, et al.
Publicado: (2022) -
A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
por: Botti, Valeria, et al.
Publicado: (2022)